Navigation Links
Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
Date:5/12/2009

- Presentation to Include Partnering Strategy and Process for Picoplatin -

SOUTH SAN FRANCISCO, Calif., May 12 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that Ronald Martell, president and chief operating officer, will present at the BIO International Convention on Tuesday, May 19, at 3:20 p.m. Eastern Time in Atlanta. Mr. Martell will provide an overview of the Company's lead product candidate, picoplatin, and outline the Company's partnering strategy and process for picoplatin.

"We believe that picoplatin's potential for technical, clinical and regulatory success in small cell lung cancer and the upcoming proof-of-concept data in the colorectal and prostate cancers programs make the compound an attractive partnering asset to pharmaceutical and biotech companies," said Mr. Martell. "We are seeking a global development and commercialization partnership for picoplatin with co-development and U.S. co-promotion rights. This global partner would share our vision that picoplatin represents a pipeline in a product and enable us to maximize the value of picoplatin worldwide."

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinatio
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... In response to its clients’ ... sales, training and consumer engagement challenges, digital ... applications to turn their clients’ visions into reality. ... mobile app creations, are now featured on its ... with Toyota, StudioPMG created a robust cross-platform mobile ...
(Date:10/1/2014)... October 01, 2014 TeselaGen Biotechnology ... Science Foundation to expand their bioCAD/CAM software suite, which ... modify DNA. The Small Business Innovation Research Phase II ... technology under exclusive license from the Lawrence Berkeley National ... Institute , an LBNL laboratory that develops alternative fuel ...
(Date:9/30/2014)... is available in German . ... several quantum dots in a semiconductor layer. Quantum dots are ... atomic processes. If a short laser pulse is fired at ... quantum dot experiences a change in the electromagnetic field around ... emission of light by the dot. As soon as the ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... Review - 2014 Summary Global Markets ... Review - 2014, provides an overview of the ... focus. This report provides comprehensive information on ... Biotechnology, LLC,s, complete with comparative analysis at various ...
Breaking Biology Technology:Digital Agency Studio PMG Launches New Case Studies on Website 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Ultrafast remote switching of light emission 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3
... Pa., Oct. 5 Genaera,Corporation (Nasdaq: GENR ... at two upcoming conferences, Biotech 2007 in Philadelphia ... San Francisco on October,9-11, 2007. Henry R. ... of Genaera, is scheduled to participate in a ...
... BASINGSTOKE, England and CAMBRIDGE, Massachusetts, October 4, Shire ... that Japan,s Ministry of Health, Labour and Welfare ... the treatment of,Hunter syndrome, for sale and marketing ... ELAPRASE is now approved for marketing and commercial,distribution ...
... Pharmasset, Inc.,(Nasdaq: VRUS ) has entered into a ... to certain terms and conditions of,the agreement, Horizon will ... its option, Pharmasset may receive a second loan of ... of $10 million by November 30, 2008,provided conditions precedent ...
Cached Biology Technology:Genaera to Present at Biotech 2007 and BIO InvestorForum 2Genaera to Present at Biotech 2007 and BIO InvestorForum 3Shire's ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome 2Shire's ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome 3Shire's ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome 4Pharmasset Accesses up to $30 Million of Working Capital 2Pharmasset Accesses up to $30 Million of Working Capital 3
(Date:10/1/2014)... , Finnland, October 1, 2014 /PRNewswire/ ... Durchbruch im Bereich der Biowissenschaften   ... ein Kommen und Gehen zahlreicher Detektionstechnologien. Einige ... zum goldenen Standard. Die Photonen-Upconversion ist eine ... letzten Jahren mit Begeisterung aufgenommen wurde. Jetzt ...
(Date:9/30/2014)... San Diego, have completed the first comprehensive numerical simulation ... the pixels in an image as data points for ... The researchers, led by J.S. Chen, the William Prager ... Engineering at UC San Diego, presented their findings on ... in Pittsburgh this month. Chen also gave a keynote ...
(Date:9/30/2014)... Calif. The National Institutes of Health (NIH) ... today to develop an electrode array system that ... brain works through unprecedented resolution and scale. , ... to support President Obama,s BRAIN (Brain Research ... research effort to revolutionize our understanding of the ...
Breaking Biology News(10 mins):Innovative Verwendungslösung für die Photonen-Upconversion 2Innovative Verwendungslösung für die Photonen-Upconversion 3First comprehensive meshfree numerical simulation of skeletal muscle tissue achieved 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3
... living in densely populated urban areas have a profound impact ... health and fitness of native wildlife. For the first time, ... urbanization and the prevalence and severity of two distinct parasites ... today,s issue of the journal PLOS ONE . ...
... made the world,s temperature records available via Google Earth. ... temperature dataset is one of the most widely used records ... allows users to scroll around the world, zoom in on ... data more easily than ever before. Users can drill ...
... Biological Studies will join Stanford University in leading a ... through a $40 million award by California,s stem cell ... center will bring together experts and investigators from seven ... of genomics the study of the complete genetic ...
Cached Biology News:Presence of humans and urban landscapes increase illness in songbirds, researchers find 2Presence of humans and urban landscapes increase illness in songbirds, researchers find 3World temperature records available via Google Earth 2Salk Institute and Stanford University to lead new $40 million stem cell genomics center 2Salk Institute and Stanford University to lead new $40 million stem cell genomics center 3
[5,6,8,9,12,14,15(n)-3H]Prostaglandin D2, 925 kBq, 25 uCi. Methanol:water:acetonitrile (3:2:1) solution.> 3.0 TBq/mmol, > 80 Ci/mmol.3.7 MBq/ml, 100 uCi/ml. Category: Radiochemicals &Radiation Safety...
One-step, microplate or cuvet, turbidometric, linear detection range 0.096 mg/dL to 11.5 mg/dL. Procedure: 5 min....
Moue Serum 8-12 Weeks Old...
... Serum • Mouse serum is collected off the clot ... weeks of age. Available Anticoagulants: N-02: ... K2EDTA N-08: Potassium Oxalate N-10: ... ACD N-07: CPD N-09: ...
Biology Products: